– USA, CA – Verge Genomics, a tech-enabled drug discovery company today announced the appointment of Dr. Al Sandrock (M.D., Ph.D.) to its Board of Directors.
“Al has personally spotted, championed, and developed more successful drugs than almost anyone in the industry. But what sets Al apart is that he is a change agent with a willingness to challenge and see what others may have missed” said Alice Zhang, CEO and co-founder of Verge Genomics.
CSO Dr. Robert Scannevin added, “I had the privilege of working with Al for almost a decade and know him to be an inspiring leader and tireless advocate for patients with neurodegenerative diseases. His bold drug discovery and development vision meshes perfectly with Verge’s innovative platform, and his experience will further augment our efforts.”
Dr. Alfred W. Sandrock, Jr.,
Dr. Sandrock joins Verge’s Board following an illustrious career in drug development. Over his 23 years at Biogen, he successfully led the discovery, development, and regulatory approval of numerous medicines, including TYSABRI, TECFIDERA, SPINRAZA, PLEGRIDY, and ADUHELM. While at Biogen, Dr. Sandrock served in positions of increasing responsibility, culminating in his service as EVP of Research and Development. He also served as CMO at Biogen and was a member of the Biogen Executive Committee for eight years.
“I have seen first-hand that one of the greatest challenges in drug discovery is deciphering biological complexity. I believe that the most promising treatments for neurological diseases in the next decade will come from using human data and next-generation technologies to drive the selection of better targets, ” said Dr. Sandrock. “After getting to know Verge over the last four years and watching all of the remarkable scientific progress they have made, I am convinced that they are leading the way in tech-enabled drug discovery. I am excited to leverage my experience to help them realize this transformative approach to biopharmaceutical R&D.”
Before joining Biogen, Dr. Sandrock was Assistant Professor of Neurology at Massachusetts General Hospital. He received his M.D. at Harvard Medical School and Ph.D. in Neurobiology at Harvard University.
About Verge Genomics
Verge uses AI and human data to develop better drugs faster for large unmet diseases. Verge has built an end-to-end drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets in neuroscience. Verge applies machine learning to reveal new targets from human datasets and develops drugs with greater probabilities of success using its human-centric biology and chemistry platforms.
Verge is the first AI-enabled drug discovery company to internally develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of its platform by delivering a broad preclinical and discovery pipeline spanning diverse therapeutic areas, with its first program, a PIKfyve inhibitor for the treatment of ALS, expected to enter the clinic in 2022. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.
For more information: https://www.vergegenomics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.